Failure of Supervised Chloroquine and Primaquine Regimen for the Treatment ofPlasmodium vivaxin the Peruvian Amazon
Abstract
The widespread use of primaquine (PQ) and chloroquine (CQ), together, may be responsible for the relatively few, isolated cases of chloroquine-resistantP. vivax(CQRPV) that have been reported from South America. We report here a case ofP. vivaxfrom the Amazon Basin of Peru that recurred against normally therapeutic blood levels of CQ. Four out of 540 patients treated with combination CQ and PQ had a symptomatic recurrence ofP. vivaxparasitemia within 35 days of treatment initiation, possibly indicating CQ failure. Whole blood total CQ level for one of these four subjects was 95 ng/ml on the day of recurrence. Based on published criteria that delineate CQRPV as aP. vivaxparasitemia, either recrudescence or relapse, that appears against CQ blood levels >100 ng/mL, we document the occurrence of aP. vivaxstrain in Peru that had unusually high tolerance to the synergistic combination therapy of CQ + PQ that normally works quite well.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 31, 2012
- Source ID
- 10.1155/2012/936067
Entities
People
- Carlos Alvarez Antonio
- Carmen Lucas
- Carmen Montalvan
- Carola Salas
- David Bacon
- David J. Fryauff
- Mariella Galves Montoya
- Meddly L. Santolalla
- Michael D. Green
- Paul C. F. Graf
- Salomon Durand
Organizations
- Centers for Disease Control and Prevention
- Naval Medical Research Center
- United States Naval Research Laboratory
- University of Rochester